INFLUENZA VIRUS EFFECTS ON MACROPHAGE VESICLE TRAFFIC
Project Number5R01AI035892-03
Contact PI/Project LeaderLOWY, ROBERT J
Awardee OrganizationHENRY M. JACKSON FDN FOR THE ADV MIL/MED
Description
Abstract Text
New and improved anti-microbial therapies are needed due to increasing
immunocompromise populations and increasing spread of drug-resistant
strains of microorganisms. Phagocytes (PC), important in pathogen
clearance, can be inhibited so effectively by pathogens that virulence
increases as PCs become the infectious agent reservoir and/or as
susceptibility to secondary infections rises. Phagocytosis and endocytosis
are among the important cellular functions suppressed by many notorious
human pathogens, including influenza virus (IV), M. leprae and M.
tuberculosis. These intracellular vesicle-based transport processes are
central to both normal PC function and to most therapies, including drug
delivery, modulation of activation and antigen processing. Not enough is
known about either the specific phagosomal-endosomal processes affected or
the physiological and biochemical mechanisms pathogens utilize to
rationally design interventions to restore PC function. The major goal of
this proposal is to determine what physiological changes occur in which
phagosome-endosome processes resulting in failure of these anti-microbial
cellular activities during IV interaction with a well-characterized
phagocytic cell the J774.1 murine macrophage. Information on macrophage-
pathogen effects is lagging that for other PCs, but during
immunosuppression they can become the predominate remaining PC. IV is an
important disease and many of its effects on PCs are similar to those of
bacteria, but it is simpler and therefore the prospect of identifying
important PC inhibitor mechanism(s) and improving anti-viral therapies is
increased. The specific aims are: 1) Identify the extent and type of
changes in macrophage intracellular trafficking pathways after exposure to
IV. 2) Determine what changes occur in the intracellular physical-chemical
environment of macrophages and intracellular compartments during early
influenza virus exposure. 3) Investigate the effects of agents which
either mimic or antagonize the IV-caused alterations in macrophage
endosome and phagosome function. Quantitative digital video microscopy
will be used to examine effects of IV on the J774 intracellular vesicle-
based transport functions including the uptake and movement between
compartments of molecular markers for specific endocytic and phagocytic
functions. fluorescent probes will also be used to monitor the physical-
chemical state of phagosomes and endosomes. It is expected that both the
methodologies and cell biological findings will be applicable to
understanding PC inhibition by other virus types, bacteria and parasites.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
144676566
UEI
UYLKBRENAPG5
Project Start Date
01-May-1994
Project End Date
31-July-1998
Budget Start Date
01-May-1996
Budget End Date
31-July-1998
Project Funding Information for 1996
Total Funding
$68,128
Direct Costs
$58,564
Indirect Costs
$9,564
Year
Funding IC
FY Total Cost by IC
1996
National Institute of Allergy and Infectious Diseases
$68,128
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI035892-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI035892-03
Patents
No Patents information available for 5R01AI035892-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI035892-03
Clinical Studies
No Clinical Studies information available for 5R01AI035892-03
News and More
Related News Releases
No news release information available for 5R01AI035892-03
History
No Historical information available for 5R01AI035892-03
Similar Projects
No Similar Projects information available for 5R01AI035892-03